If one pulls up last years October investor day Necuparanib presentation graph and compare it to the graph presented in this Stifel presentation, the time lapsed is about eight months... which means that the graph presented by Rick is the one presented at the June 1,2015 ASCO conference... 6 months ago!...
This additional 6 months will make the Median OS with the Necuparanib dose easily double that of the Gem + ABX dose alone... and the crazy part is it is still ongoing... moo k
If the patients that MNTA is still gathering data on is still on treatment in phase I, it means that they either have PR or SD... in this group getting a CR on one or more patient(s) would be fantastic ... moo k
Blackrock filed an SC 13G/A November 10.. they now own 7.02 million collective shares.
Parsing the Necu+ Ab + Gem phase 1 graph...
Median OS 14.2 months greater than 1 necu dose, 15.3 months greater than or equal to 1 necu cycle
for comparison Ab + Gem alone has median OS of ~ 8.7months
8 PR, 6 SD..
11 patients ongoing! ... (6 PR, 3 SD, 2 Off Treatment)
5 still On Treatment... (4 PR and 1 SD)
Interesting that the 4mg/kg seem as effective as 5mg/kg... maybe they should have used this as the phase 2 dose...
ibly. I think this one becomes a story stock launching in 2016!
JAcob Gottlieb's fund second largest holder with 5.4 million SHARES added since the summer. If the ruling goes against Amphastar, Teva and Allergan a $billion judgement doubles the market share instantly!
I still believe the Necuparinib potential is a true game changer in addition to Humira eventually getting launched along with twice a week Copaxone or Teva's latest version. It is coming soon!
Rick Shea,Toast Masters is a good club to join... They will help you eliminate or iron out the a-ahhs and the uhmms and other crutch words making a presentation more effective and easier to listen to...
Check out the accompanying slides in this webcast... very informative...
The new phase 1 graph on Necu is more mature now and is looking good... there's a lot of Partial Responses... and again OS is now excellent but will still improve as they track those patients that are still in the phase 1 study... moo k
Momenta's share of generic Enox is $359 Million in 5 Quarters --- from 3rdQ of 2010 (Momenta's generic Enox first came to market) to 3rdQ 2011 (When Amphastar's generic Enox came to market) ...
That is an average of $71.6 Million per quarter... multiply that by 16 Quarters... from 3Q 2011 to now (3Q 2015 )and we get $1.1456 Billion... this is the total potential revenue MNTA lost from Amphastar's generic entry... treble that and we get ~$3.4 Billion...
I think Amphastar infringed on MNTA's patents and is guilty... which means its partner Watson aka Actavis aka Allergan is on the hook because Amphastar can't pay that amount... funny thing is Allergan is bought by TEVA recently... so TEVA may still be on the hook... moo k
see Clovis (CLVS) to see what I mean... the other day it was trading around $100. today ~$27... taking down major institutional holders on the way.... moo k
Trouble is they will be out of money again before new products reach the market with the current rate of cash burn, which would mean another attempt with dilution selling more stock to raise cash.
in biotech world, solid information today may easily get trumped by news the following day.
my advice... be nimble and quick bearing in mind that Momenta's main trajectory is upwards. how fast we will get there? i'm giving it 3 years....
JPMorgan analyst Chris Schott started shares of Momenta Pharmaceuticals with an Overweight rating and $26 price target. Glatopa, or generic Copaxone, is a key near-term value-driver for the company, Schott tells investors in a research note
Sentiment: Strong Buy
I know you hold a great deal of this stock. Would you elaborate on the short and long term growth potential for MNTA ? You seem to have solid information to give solid advice.
My letter to Sarah Carmody at Momenta iR
RE: Phase I Necuparanib
Dear Ms.Carmody in the 3rd Q CC Craig Wheeler says the phase 1 study is ongoing. are there patients still alive? how many? Thanks, Kainoa
Nov 9 at 1:07 PM
Thank you for your email. There are still patients that we are collecting data on from Phase 1 study. We have not publically disclosed any further information at this point.
Associate Director, Investor Relations & Corporate Communications
675 West Kendall Street
Cambridge | MA 02142 | USA
momenta have good science but poor legal/ business development team that seem to continuously outmaneuver by the big and small players, teva and amphastar, that continually depress their sales by lawyering them to death...unless there is some sort of treble damages, momenta will have to eat this and learn their lessons on how to defend their ip better with their glatirimer
There is almost no float in MNTA considering that insiders and institutional holdings account for most of the float.
Blackrock decreased that float even more.
The CAFC ruling should slowly help boost the share price.
Good news: They reverse the lower court and now hold that the 271(e)(1) safe harbor does not protect Amphastar, "The conclusion in Momenta I that Amphastar’s commercial use of Momenta’s patented method falls within the safe harbor of §271(e)(1) would result in manifest injustice."
Bad News: Dismissal of the claim against TEVA, as that is based on Section 271(g) and requires that TEVA have used the Momenta patent to "make" the product, and the court find the patent was not so used.
No bump in stock price yet. Maybe if MNTA releases a PR? AMPH is flat too.
Sentiment: Strong Buy
I'll keep this short and sweet...Google "PennyStock101' signup for their free newsletter and get their next trade alert. Come back and thank me tomorrow!
it is highly likely that some patients that had greater than or equal to 90% decreases of CA 19.9 are still alive... it is possible that 9 patients are still in the study, many of whom had partial response - 3 from cohort 5 (4mg/kg), 1 patient from cohort 6 (6mg/kg), and upwards to 5 patients in cohort 7 (5mg/kg-MTD dose) ... k
June 1st, 2015 presentation...
For the 24 patients in cohorts 3-7 who received at least one dose of necuparanib + nabP + GEM, the median overall survival (OS) was 14.2 (95% CI, 9.3-16.0) months.
◦ Sixteen patients were treated with necuparanib + nabP + GEM, completed Cycle 1, and had ≥1 scan on treatment; of these, eight (50%) achieved RECIST partial response (PR) and six (38%) more achieved stable disease (SD), for a disease control rate (PR+SD) of 14/16 (88%). Median OS was 15.3 (95% CI, 9.7-16.0) months in this subset.
◦ Fifteen patients were treated with necuparanib + nabP + GEM, completed Cycle 1, and had ≥1 follow-up CA19.9 measurement; of these, 15 (100%) had 20%, 14 (93%) had 50%, and seven (47%) had 90% decreases from baseline (CA19.9 is a biomarker predictive for long-term outcome and treatment response in pancreatic cancer).
Add 5 more months to OS and we have a very very potent drug... it more than doubles the standard of care...
and it is still ongoing!.... we clearly have a winner here... mooo k